PHENYLBUTAZONE paste

מדינה: ארצות הברית

שפה: אנגלית

מקור: NLM (National Library of Medicine)

מרכיב פעיל:

Phenylbutazone (UNII: GN5P7K3T8S) (Phenylbutazone - UNII:GN5P7K3T8S)

זמין מ:

Covetrus North America

מסלול נתינה (של תרופות):

ORAL

סוג מרשם:

PRESCRIPTION

סממני תרפויטית:

INDICATIONS: For the relief of inflammatory conditions associated with the musculoskeletal systems in horses. CONTRAINDICATIONS: Use with caution in patients who have a history of drug allergy.

leaflet_short:

HOW SUPPLIED: Syringes containing 20 g of Phenylbutazone.

מצב אישור:

Abbreviated New Animal Drug Application

מאפייני מוצר

PHENYLBUTAZONE- PHENYLBUTAZONE PASTE
COVETRUS NORTH AMERICA
----------
PHENYLBUTAZONE
PASTE FOR HORSES
NDC 11695-4858-1
ANADA 200-266, Approved by the FDA.
_FOR ANIMAL USE ONLY_
DESCRIPTION: Phenylbutazone Paste is a synthetic, non-hormonal
anti-inflammatory, antipyretic
compound useful in the management of inflammatory conditions. The
apparent analgesic effect is
probably related mainly to the compound's anti-inflammatory
properties. Chemically, Phenylbutazone
Paste is 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione. It is a
pyrazolone derivative, entirely unrelated to
the steroid hormones.
INDICATIONS: For the relief of inflammatory conditions associated with
the musculoskeletal systems
in horses.
CONTRAINDICATIONS: Use with caution in patients who have a history of
drug allergy.
WARNING: NOT FOR USE IN HORSES INTENDED FOR FOOD.
PRECAUTIONS: Stop medication at the first sign of gastrointestinal
upset, jaundice, or blood
dyscrasia. Authenticated cases of agranulocytosis associated with the
drug have occurred in man; fatal
reactions, although rare, have been reported in dogs after long-term
therapy. To guard against this
possibility, conduct routine blood counts at weekly intervals during
the early phase of therapy and at
intervals of two weeks thereafter. Any significant fall in the total
white blood cell count, relative
decrease in granulocytes, or black or tarry stools should be regarded
as a signal for immediate
cessation of therapy and institution of appropriate counter-measures.
In the treatment of inflammatory
conditions associated with infections, specific anti-infective therapy
is required.
ADMINISTRATION AND DOSAGE: Orally - 1 to 2 g of phenylbutazone per 500
lb. of body weight
daily. Do not exceed 4 g daily.
GUIDELINES TO SUCCESSFUL THERAPY: Use a relatively high dose for the
first 48 hours, then reduce
gradually to a maintenance dose. Maintain the lowest dose capable of
producing desired clinical
response. Response to Phenylbutazone Paste therapy is prompt, usually
occurring within 24 hours. If no
signif